La transparencia o apariencia de ella en la regulación sobre la financiación selectiva de la prestación farmacéuticaEl sistema de fijación de los precios de los medicamentos en España

  1. Luis Miguel García Lozano 1
  1. 1 Universidad Carlos III de Madrid
    info

    Universidad Carlos III de Madrid

    Madrid, España

    ROR https://ror.org/03ths8210

Journal:
DS : Derecho y salud

ISSN: 1133-7400

Year of publication: 2019

Issue Title: Extraordinario XXVIII Congreso 2019: Ética, innovación y transparencia en salud

Volume: 29

Issue: 1

Pages: 118-132

Type: Article

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: DS : Derecho y salud

Abstract

The determination of the prices of medicines and other medical devices has always been a headache on the part of the State, since they are products of great importance for the health and well-being of citizens. However, the legislator must assess above all two aspects: the possibility of generalized access to pharmacological and health products and, on the other hand, the remuneration for the creation, the right given by the patent that is exploited and the manufacture of the product. For this, the legislator has had to design a pricing system based on various variables that ensure these variables, but also partly finance the product with public funds so that the part of society with less economic passibilities can access these types of Products on equal terms.

Data source: Dialnet